

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method of enhancement of an immune response and immunomodulating activity comprising intraperitoneally or subcutaneously administering to a subject an effective amount of an adjuvant composition with synergistic effect comprising ~~an iscom particle immunostimulating complex (ISCOM) particles~~ comprising fraction A of Quil A together with at least one other adjuvant, wherein the at least one other adjuvant is in free form or integrated into another separate ~~iscom particle~~ ISCOM particles other than the ISCOM particles in which one in which the fraction A of Quil A is [[was]] integrated.
2. (Previously Presented) The method according to claim 1 wherein said at least one other adjuvant is chosen from the group consisting of: saponins, naturally occurring saponin molecules derived from crude saponin extract of Quillaja saponaria Molina, synthetic saponin molecules derived from crude saponin extract of Quillaja saponaria Molina, semisynthetic saponin molecules derived from crude saponin extract of Quillaja saponaria Molin, saponin fractions from Quil A, saponin fractions from cell wall skeleton, blockpolymers, hydrophilic block copolymers, CRL-1005, Threhalose di mucolate (TDM), lipopeptides, LPS derivatives, LPS-derivatives, Lipid A from a bacterial species and derivatives thereof, monophosphoryl lipid A, CpG variants, CpGODN variants, endogenous human animal immunomodulators, GM-CSF, IL-2, native adjuvant active bacterial toxins, modified adjuvant active bacterial toxins, cholera toxin CT, CT subcomponent CTB, CT subcomponent CTA1, thermolabile toxin (LT) of *E. coli*, *Bordetella pertussis* (BP) toxin, and a filamentous heamagglutinin of BP.
3. (Previously Presented) The method according to claim 2 wherein the saponin fraction from Quil A is fraction C of Quil A or fraction B of Quil A.

4. (Currently Amended) The method according to claim 1, wherein said at least one other adjuvant is integrated into one ~~iscom~~ particle ISCOM particles.
5. (Currently Amended) The method according to claim 1, wherein said fraction A of Quil A is integrated into a ~~first iscom~~ particle ISCOM particles and said at least one other adjuvant is integrated into a ~~second iscom~~ particle ISCOM particles other than the ISCOM particles in which fraction A of Quil A is integrated.

Claim 6. (Canceled).

7. (Currently Amended) The method according to claim 4, wherein said fraction A of Quil A is integrated into one [[iscom]] ISCOM particle and said at least one other adjuvant is not integrated into [[iscom]] ISCOM particle.
8. (Previously Presented) The method according to claim 7, wherein said at least one other adjuvant is at least one of monophosphoryl lipid A and cholera toxin CT.
9. (Currently Amended) The method according to claim 4, wherein said [[iscom]] ISCOM particle is an [[iscom]] ISCOM complex.
10. (Currently Amended) The method according to claim 4, wherein said [[iscom]] ISCOM particle is an [[iscom]] ISCOM matrix complex.
11. (Currently amended) The method according to claim 3, wherein the composition comprises
50-99.9% of fraction fragment A of Quil A; and
0.1-50% of ~~a fraction or derivative of the saponin~~ fraction of Quil A based on the total weight of the composition.

12. (Currently amended) The method according to claim 11, wherein the composition comprises

75-99.9% of fraction fragment A of Quil A; and

0.1-25% ~~of a fraction or derivative of the saponin fraction~~ of Quil A based on the total weight of the composition.

13. (Currently amended) The method according to claim 12, wherein the composition comprises

91-99.1 % of fraction fragment A of Quil A; and

0.1-9% ~~of a fraction or derivative of the saponin fraction~~ of Quil A based on the total weight of the composition.

14. (Previously Presented) The method according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or additive.